Revolutionizing Personalized Healthcare with Data-Based Insights
The leading pioneer in biology since 1896, Roche develops innovative medicines, treatments and diagnostics that revolutionize healthcare.
Throughout a 125-year history, Roche has grown into one of the world’s largest biotech companies, a leading provider of in-vitro diagnostics, and a global supplier of transformative innovative solutions across major disease areas.
Roche’s instruments are getting faster with higher resolution at lower granularity, and they understood they were facing a parallel data problem. They chose NVIDIA GPUs as the parallel processing engine complemented by DDN A³I storage, allowing the information to be generated quickly, processed rapidly, and produced faster results more efficiently – enabling Roche to unlock early cancer detection when it matters most.
Genome Sequencing at Scale with NVIDIA H100 & DDN
Challenges
Being 100% cloud based worked fine early in their development, but after adding additional sensors and generating more data – up to 2PB every 24 hours – it became too cumbersome and slow to continue with that strategy. Limitations of being fully cloud-based required users to compromise their analysis and discard 99% of their data. Turnaround time for critical experiments was over two weeks.
Solution
An end-to-end solution backed by hybrid NVME and dense disk storage for Nanopore Sequencing
DDN A³I with NVIDIA H100 GPUs for a fast system in a small footprint
Simple expansion with standard building blocks Roche
Benefits
- Decreased analysis turnaround time by more than 7X (from 15 days to 2 days)
- Allowed them to keep and analyze more data
- Reduced the amount of data uploaded to the cloud by 100X
QuoteThe solution DDN had, for what we needed, just made sense. We needed a small footprint and something very fast so we could process the data as quickly as possible – time is money.
Chuck SeberinoDirector of Accelerated Computing Roche Sequencing Solutions
